• 대한핵의학회지
• /
• 제30권4호
• /
• pp.524-531
• /
• 1996

목적 : 골스캔에서 신세포암의 골전이 빈도, 호발 부위 및 전이 양상을 알아보고, 신세포암이 있는 신장의 섭취 형태를 분류하여 신세포암 환자에서 골스캔의 부가적 역할을 알아보고자 하였다. 방 법 : 수술과 조직 검사상 신세포암으로 진단된 158명의 골스캔을 후향적으로 분석하였으며 골스캔상 병변은 방사선학적인 검사와 추적 골스캔, 조직 검사 소견을 통하여 골전이를 확인하였다. 골스캔상 전이 병소의 위치는 두개골, 척추, 견관절, 흉골, 늑골, 골반, 사지의 장골등 7개의 해부학적 위치로 나누었고, 각 병변은 열소와 냉소로 분류하였다. 신세포암을 가진 신장은 섭취 형태에 따라 정상, 광자결손병소, 크기가 커져 있으면서 약한 섭취를 보이는 경우 크기가 커져 있으면서 불규칙한 섭취를 보이는 경우, 초승달 모양으로 밀려 있는 경우 그리고 섭취가 증가되어 있는 경우 등 여섯 군으로 분류하였다. 결 과 : 158명의 환자중 20명(12.7%)에서 71개의 골전이 병변을 관찰할 수 있었고 전체 병변의 약 80%는 구간 골격에 위치하였다. 병변중 55개(77.5%)는 열소로, 16개(22.5%)는 냉소로 보였다. 첫 골스캔을 시행하기 전에 신절제술을 받은 20명의 환자를 제외한 138명의 환자중 70명 (50.7%)에서 비정상 신섭취를 관찰할 수 있었으며, 그 중 골전이가 있는 17명(3명은 첫 골스캔 전에 신절제술을 받았음)의 환자중에서는 14명(82.4%)에서 비정상 신섭취를 관찰할 수 있었다. 비정상 신섭취를 보이는 70명중에서 가장 흔한 두 가지 형태는 광자결손병소와 크기가 커져있으면서 약한 섭취를 보이는 경우로 각각 35명(50%)과 17명(24.3%)이었다. 그리고 골의 통증과 병적 골절을 주소로 내원한 4명의 환자에서는 골스캔상 비정상 신섭취와 골의 병소를 관찰함으로써 인식되지 못했던 원발 종양(신세포암)에 대한 정보를 제공할 수 있었다. 결 론 : 골스캔상 신세포암으로부터의 골전이 병소의 양상과 신섭취 형태를 잘 이해함으로써 골전이 병소를 잘 검출할 수 있을 뿐 아니라, 원발 종양에 대한 정보를 제공할 수 있으리라 생각된다.

• Nuclear Medicine and Molecular Imaging
• /
• 제41권3호
• /
• pp.260-262
• /
• 2007

A 68-year-old man with small cell carcinoma of the lung and adenocarcinoma of the prostate underwent Tc-99m MDP bone scintigraphy for the evaluation of skeletal metastases. Bilateral symmetrical photon defects in both parietal bones of the skull were observed. The radiographs of the skull demonstrates biparietal thinning in the same area of the abnormality identified on bone scintigraphy. Although these findings in cancer patients can be mistaken for skeletal metastases, the symmetry and location of the photon defects are generally indicative of biparietal thinning.

• Nuclear Engineering and Technology
• /
• 제55권1호
• /
• pp.254-260
• /
• 2023

Skeletal metastases are common in patients suffering from various primary cancers. Radiopharmaceuticals are an effective option for bone pain palliation. In this work, the radiation absorbed dose of ¹⁷⁷Lu-EDTMP radiopharmaceutical was estimated for adult man based on biodistribution data in Wistar rats. The MIRD dose calculation method and the Sparks and Aydogan methodology were applied. The results shows that about 46% of injected activity is cumulated on the surface of the trabecular and cortical bones. Radiation absorbed doses of red bone marrow and osteogenic cells were estimated to about 1.1 and 6.2 mGy/MBq, respectively. The maximum administrated activity was obtained 27 MBq/kg of body weight with an effective dose of 0.23 mSv/MBq. The results were compared with other available data from literature. This study indicated that ¹⁷⁷Lu-EDTMP provides therapeutic efficacy for achieving bone pain palliation with low undesired dose to other normal organs.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권1호
• /
• pp.61-67
• /
• 2014

Background: Solid cancers with bone marrow metastases are rare but lethal. This study aimed to identify clinical factors predictive of survival in adult patients with solid cancers and bone marrow metastases. Methods: A total of 83 patients were enrolled consecutively between January 1, 2000 and December 31, 2012. Bone marrow metastases were confirmed by biopsies. Patient clinical features and laboratory data were analyzed for associations. Results: The median age of the patients was 54 years (range, 23-88 years), and 58% were male. The 3 most common primary tumor locations were the stomach (32 patients, 39%), prostate (16 patients, 19%), and lungs (12 patients, 15%). The median overall survival was 49 days (range, 3-1423 days). Patients with Eastern Cooperative Oncology Group performance status 1, cancers of prostate origin, platelet counts over 50,000/ml, and undergoing antitumor therapies had a significantly better prognosis in the multivariate analysis. The median survival times were 173 and 33 days for patients with 2-3 more favorable parameters (n=24) and those with 0-1 (n=69), respectively (hazard ratio 0.30; 95% CI 0.17-0.52, p<0.001). Conclusions: Solid cancers with bone marrow metastases are dismal and incurable diseases. Understanding prognostic factors to these diseases helps medical personnel to provide appropriate treatments and better inform patients about outcomes. Antitumor therapies may improve outcomes in selected patient cohorts.

• The Korean Journal of Pain
• /
• 제26권3호
• /
• pp.223-241
• /
• 2013

Boney metastasis may lead to terrible suffering from debilitating pain. The most likely malignancies that spread to bone are prostate, breast, and lung. Painful osseous metastases are typically associated with multiple episodes of breakthrough pain which may occur with activities of daily living, weight bearing, lifting, coughing, and sneezing. Almost half of these breakthrough pain episodes are rapid in onset and short in duration and 44% of episodes are unpredictable. Treatment strategies include: analgesic approaches with "triple opioid therapy", bisphosphonates, chemotherapeutic agents, hormonal therapy, interventional and surgical approaches, steroids, radiation (external beam radiation, radiopharmaceuticals), ablative techniques (radiofrequency ablation, cryoablation), and intrathecal analgesics.

• 대한골관절종양학회지
• /
• 제14권2호
• /
• pp.86-94
• /
• 2008

$^{18}F$-FDG PET/CT는 해부학적 영상과 함께 생리적인 변화를 보여주는 영상을 동시에 제공함으로써 진단적 영상검사에 많은 발전을 가져왔고, 근골격계 종양을 평가하는데 새롭고 독창적인 방법으로 등장 하였다. 최근 PET/CT는 골 전이를 찾는데, 골 연부조직 종양의 시기 결정 및 재시기 결정에 많이 사용되고 있다. 또한 악성 근골격계 종양의 치료에 대한 평가와 치료 후 추시에서 국소 재발이나 원격 전이를 찾아내는 데 유용하게 사용되고 있다. 향후 근골격계 종양에 대한 PET/CT의 연구 자료가 축적되고, 발전된다면 초기 진단에도 유용하게 쓰일 수 있을 것으로 사료된다. 이 논문은 근골격계 종양의 평가를 위한 $^{18}F$-FDG PET/CT의 효율적인 적용에 대하여 문헌 고찰과 함께 살펴보고자 한다.

• Radiation Oncology Journal
• /
• 제12권2호
• /
• pp.201-207
• /
• 1994

To objectively compare the response of the palliative radiotherapy in bone metastatic patients which decreases pain and prevents pathologic fractures, we introduced and applied the RTOG pain and narcotic measure system. From Oct in 1991 to July in 1993, thirty-two patients with painful bone metastases, 17 of them were solitary lesions and others were multiple lesions, were treated with mainly 6 MV photon otherwise 15 MV photon. Radiation doses to bone metastatic sites ranged about from 2000 to 4600cGy. Responses of radiation therapy were compared with days of pre-RT, RT finish, 3, 6, 9 months after the start of RT and solitary versus multiple lesions and follow up scores according to the RTOG measure system. Survival analysis was done. Pain and narcotic score of the entire patients were 7.3, 7.8 at the pre-RT period and 2.6, 3.9 at the immediate or 2 weeks after RT, which was $64{\%},\;50{\%}$ decrement compared with the pre-RT score, Pain scores of 3, 6 and 9 months after the beginning of irradiation were 3.6, 3.7 and 3.3. The best response found in the breast and prostate primaries was $84\%,\;78\%$ decrement of pain score as compared with pre-RT score(statistically insignificant). Median survival was 5.5 months and mean survival was 5 months. We conclude that the RTOG pain and narcotic measure system is relatively effective scale in the comparison of before and after palliative irradiation to the painful bone metastatic sites but more detailed parameters will be required in the narcotic scoring system. More aggressive but less or similiar toxic radiotherapy is needed in the patients having relatively long life expected time.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권1호
• /
• pp.387-391
• /
• 2015

Background: Fluorine-18 deoxyglucose positron emission tomography computed tomography (18F-FDG-PET/CT) and bone scintigraphy (BS) are widely used for the detection of bone involvement. The optimal imaging modality for the detection of bone metastases in hormone receptor positive (+) and negative (-) groups of breast cancer remains ambiguous. Materials and Methods: Sixty-two patients with breast cancer, who had undergone both 18F-FDG-PET/CT and BS, being eventually diagnosed as having bone metastases, were enrolled in this study. Results: 18F-FDG-PET/CT had higher sensitivity and specificity than BS. Our data showed that 18F-FDGPET/CT had a sensitivity of 93.4% and a specificity of 99.4%, whiel for BS they were 84.5%, and 89.6% in the diagnosis of bone metastases. ${\kappa}$ statistics were calculated for 18F-FDGPET/CT and BS. The ${\kappa}$-value was 0.65 between 18F-FDG-PET/CT and BS in all patients. On the other hand, the ${\kappa}$-values were 0.70 in the hormone receptor (+) group, and 0.51 in hormone receptor (-) group. The ${\kappa}$-values suggested excellent agreement between all patient and hormone receptor (+) groups, while the ${\kappa}$-values suggested good agreement in the hormone receptor (-) group. Conclusions: The sensitivity and specificity for 18F-FDG-PET/CT were higher than BS in the screening of metastatic bone lesions in all patients. Similarly 18F-FDG-PET/CT had higher sensitivity and specificity in hormone receptor (+) and (-) groups.

• Clinics in Shoulder and Elbow
• /
• 제24권2호
• /
• pp.110-113
• /
• 2021

We present an unusual case of bone metastases from renal cell carcinoma around orthopedic implants in a 78-year-old female with osteolytic, expansile, highly vascularized, malignant infiltration around suture anchors in the proximal humerus. The patient had undergone arthroscopic rotator cuff repair using suture anchor implants 6 years previously. After diagnosis of bone metastasis, she was successfully treated with metastasectomy and internal fixation using a plate and screws, with cement augmentation. This report is the first to document metastases around a suture anchor in a bone and suggests the vulnerability of suture anchor implants to tumor metastasis.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권9호
• /
• pp.4335-4340
• /
• 2016

Background: Bone metastasis is a single condition but presents with various patterns and severities. Skeletal-related events (SREs) deteriorate overall performance status and reduce quality of life. However, guidelines for early detection and management are limited. This study includes a survey of the prevalence of bone metastasis in cases with common cancers in Thailand as well as a focus on survival patterns and SREs. Materials and Methods: A retrospective cohort analysis was conducted using a database of the Chiang Mai Cancer Registry and the Musculoskeletal Tumor Registry of the OLARN Center, Chiang Mai University. The prevalence of bone metastasis from each type of primary cancer was noted and time-to-event analysis was performed to estimate cancer survival rates after bone metastasis. Results: There were 29,447 cases of the ten most common cancers in Thailand, accounting for 82.2% of the entire cancer registry entries during the study period. Among those cases, there were 2,263 with bone metastases, accounting for 7.68% of entries. Bone metastasis from lung, liver, breast, cervix and prostate are common in the Thai population, accounting for 83.4% of all positive cases. The median survival time of all was 6 months. Of the bone metastases, 48.9% required therapeutic intervention, including treatment of spinal cord and nerve root compression, pathological fractures, and bone pain. Conclusions: The frequency of the top five types of bone metastasis in Thailand were different from the frequencies in other countries, but corresponded to the relative prevalence of the cancers in Thailand and osteophilic properties of each cancer. The results of this study support the establishment of country specific guidelines for primary cancer identification with skeletal lesions of unknown origin. In addition, further clinical studies of the top five bone metastases should be performed to develop guidelines for optimal patient management during palliative care.